select a format

Single User License
USD 2000 INR 130880
Site License
USD 4000 INR 261760
Corporate User License
USD 6000 INR 392640

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


High-Grade Glioma-Pipeline Review, H2 2016

High-Grade Glioma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8917IDB
  • |
  • Pages: 162
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

High-Grade Glioma-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma-Pipeline Review, H2 2016, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated appetite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).

The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

High-Grade Glioma Overview 9

Therapeutics Development 10

Pipeline Products for High-Grade Glioma-Overview 10

Pipeline Products for High-Grade Glioma-Comparative Analysis 11

High-Grade Glioma-Therapeutics under Development by Companies 12

High-Grade Glioma-Therapeutics under Investigation by Universities/Institutes 14

High-Grade Glioma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

High-Grade Glioma-Products under Development by Companies 18

High-Grade Glioma-Products under Investigation by Universities/Institutes 19

High-Grade Glioma-Companies Involved in Therapeutics Development 20

Advenchen Laboratories LLC 20

AngioChem Inc 21

Arog Pharmaceuticals Inc 22

Astellas Pharma Inc 23

Athenex Inc 24

Bayer AG 25

BTG Plc 26

Cavion LLC 27

CBT Pharmaceuticals Inc 28

DelMar Pharmaceuticals Inc 29

Merrimack Pharmaceuticals Inc 30

Millennium Pharmaceuticals Inc 31

Nektar Therapeutics 32

Novartis AG 33

Sanofi 34

Sumitomo Dainippon Pharma Co Ltd 35

Targepeutics Inc 36

Tocagen Inc 37

Virttu Biologics Ltd 38

ZIOPHARM Oncology Inc 39

High-Grade Glioma-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Combination Products 41

Assessment by Target 42

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

AdRTSIL-12-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

alisertib-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

apatinib-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

bendamustine hydrochloride-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

BMX-001-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

cabazitaxel-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

CBT-101-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Cellular Immunotherapy for Gliomas-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Cellular Immunotherapy for High-Grade Glioma-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Cellular Immunotherapy for Oncology-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

crenolanib besylate-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

dabrafenib mesylate-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

dabrafenib mesylate + trametinib dimethyl sulfoxide-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

dianhydrogalactitol-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

DSP-7888-Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

etirinotecan pegol-Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

flucytosine + TBio-01-Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

flucytosine ER + vocimagene amiretrorepvec-Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

GB-13-Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

HSV-1716-Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

irinotecan hydrochloride-Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

irinotecan hydrochloride + TBio-02-Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

irinotecan hydrochloride CR-Drug Profile 135

Product Description 135

Mechanism Of Action 135

R&D Progress 135

KX-02-Drug Profile 136

Product Description 136

Mechanism Of Action 136

R&D Progress 136

mibefradil dihydrochloride-Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

Oncolytic Virus for High-Grade Glioma and Melanoma-Drug Profile 141

Product Description 141

Mechanism Of Action 141

R&D Progress 141

paclitaxel trevatide-Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

RRX-001-Drug Profile 147

Product Description 147

Mechanism Of Action 147

R&D Progress 147

sorafenib tosylate-Drug Profile 149

Product Description 149

Mechanism Of Action 149

R&D Progress 149

High-Grade Glioma-Dormant Projects 156

High-Grade Glioma-Discontinued Products 157

High-Grade Glioma-Product Development Milestones 158

Featured News & Press Releases 158

Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 158

May 28, 2015: Cavion to Present Clinical Trial Data at ASCO 159

May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin-Refractory High-Grade Glioma Presented at 50th ASCO Meeting 159

Appendix 161

Methodology 161

Coverage 161

Secondary Research 161

Primary Research 161

Expert Panel Validation 161

Contact Us 161

Disclaimer 162

List of Figures

Number of Products under Development for High-Grade Glioma, H2 2016 10

Number of Products under Development for High-Grade Glioma-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Top 10 Targets, H2 2016 42

Number of Products by Stage and Top 10 Targets, H2 2016 42

Number of Products by Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 47

Number of Products by Stage and Routes of Administration, H2 2016 47

Number of Products by Molecule Types, H2 2016 49

Number of Products by Stage and Molecule Types, H2 2016 49

List of Tables

Number of Products under Development for High-Grade Glioma, H2 2016 10

Number of Products under Development for High-Grade Glioma-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

High-Grade Glioma-Pipeline by Advenchen Laboratories LLC, H2 2016 20

High-Grade Glioma-Pipeline by AngioChem Inc, H2 2016 21

High-Grade Glioma-Pipeline by Arog Pharmaceuticals Inc, H2 2016 22

High-Grade Glioma-Pipeline by Astellas Pharma Inc, H2 2016 23

High-Grade Glioma-Pipeline by Athenex Inc, H2 2016 24

High-Grade Glioma-Pipeline by Bayer AG, H2 2016 25

High-Grade Glioma-Pipeline by BTG Plc, H2 2016 26

High-Grade Glioma-Pipeline by Cavion LLC, H2 2016 27

High-Grade Glioma-Pipeline by CBT Pharmaceuticals Inc, H2 2016 28

High-Grade Glioma-Pipeline by DelMar Pharmaceuticals Inc, H2 2016 29

High-Grade Glioma-Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 30

High-Grade Glioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 31

High-Grade Glioma-Pipeline by Nektar Therapeutics, H2 2016 32

High-Grade Glioma-Pipeline by Novartis AG, H2 2016 33

High-Grade Glioma-Pipeline by Sanofi, H2 2016 34

High-Grade Glioma-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 35

High-Grade Glioma-Pipeline by Targepeutics Inc, H2 2016 36

High-Grade Glioma-Pipeline by Tocagen Inc, H2 2016 37

High-Grade Glioma-Pipeline by Virttu Biologics Ltd, H2 2016 38

High-Grade Glioma-Pipeline by ZIOPHARM Oncology Inc, H2 2016 39

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 46

Number of Products by Stage and Route of Administration, H2 2016 48

Number of Products by Stage and Molecule Type, H2 2016 50

High-Grade Glioma-Dormant Projects, H2 2016 156

High-Grade Glioma-Discontinued Products, H2 2016 157

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advenchen Laboratories LLC, AngioChem Inc, Arog Pharmaceuticals Inc, Astellas Pharma Inc, Athenex Inc, Bayer AG, BTG Plc, Cavion LLC, CBT Pharmaceuticals Inc, DelMar Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, Millennium Pharmaceuticals Inc, Nektar Therapeutics, Novartis AG, Sanofi, Sumitomo Dainippon Pharma Co Ltd, Targepeutics Inc, Tocagen Inc, Virttu Biologics Ltd, ZIOPHARM Oncology Inc

High-Grade Glioma Therapeutic Products under Development, Key Players in High-Grade Glioma Therapeutics, High-Grade Glioma Pipeline Overview, High-Grade Glioma Pipeline, High-Grade Glioma Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com